Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women | Zendy

Céline Straczek | Zendy; Emmanuel Oger | Zendy; Marianne Caico | Zendy; Geneviève PluBureau | Zendy; Jacqueline Conard | Zendy; Guy Meyer | Zendy; Martine AlhencGelas | Zendy; H. Lévesque | Zendy; Nathalie Trillot | Zendy; M.T. Barrellier | Zendy; Denis Wahl | Zendy; Joseph Emmerich | Zendy; PierreYves Scarabin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women

Author(s) -

Céline Straczek,

Emmanuel Oger,

Marianne Caico,

Geneviève PluBureau,

Jacqueline Conard,

Guy Meyer,

Martine AlhencGelas,

H. Lévesque,

Nathalie Trillot,

M.T. Barrellier,

Denis Wahl,

Joseph Emmerich,

PierreYves Scarabin

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.565556

Subject(s) - medicine , odds ratio , estrogen , factor v leiden , risk factor , gastroenterology , confidence interval , factor v , gynecology , venous thrombosis , thrombosis

Oral estrogen increases the risk of venous thromboembolism (VTE) in postmenopausal women, particularly in those with a prothrombotic mutation. Transdermal estrogen may be safe with respect to VTE. We investigated the impact of the route of estrogen administration on the association between a prothrombotic mutation (factor V Leiden or prothrombin G20210A mutation) and VTE risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research